- Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
- Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
- Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.